🎧 How can MSIntuit® CRC empower pathologists to optimize MSI testing for colorectal cancer with H&E slides? Hear our Lead Data Scientist Rémy Dubois explain our poster at #USCAP24 .

Catch the poster presentation on Wednesday, March 27 at 1:00pm - 4:30pm EDT at the Baltimore…

Powerful paper Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) congratulations

nature.com/articles/s4158…

Dans le 12e épisode de DeepTechs, Gilles Fontaine et Guillaume Payan reçoivent Thomas Clozel, co-fondateur d’Owkin, pour parler médecine de précision et détection de cancers grâce à l’IA

➡️ linktr.ee/Deeptechs

Owkin’s AI is #accelerating and #augmenting #biology : today we deep dive into MesoNet – an Owkin-built interpretable #AI model for predicting the survival of mesothelioma patients from whole slide digital images.👇

Execution and culture are 10x more important than strategy in the early stages of building a company.

It doesn't matter how slick your strategy is if your team can't build something people want to to buy. Besides, whatever strategy you have before figuring out what the customer…

Owkin has been recognized by Forbes as one of America's Best Startup Employers in 2024, designating it as one of the best-performing startups - as employers - through defined KPIs.

Thank you, Forbes, and congrats to all winners! 🏆

forbes.com/lists/americas…

Is #AI currently delivering a return on investment? 👀Our Co-founder and CEO, Thomas Clozel, participated in a panel 'Creating ROI from AI' hosted by Endpoints News at #JPM24 .

Access the full HD recording here owkin.com/connect/jpm-pa…

#healthtech #datascience #biology

Last week Alexandre Boussommier and Thomas Clozel, joined us at our AI Startup School in Paris, to share their journeys building AI biotech startups.

AI-powered SaaS platform, ImVitro is tackling the global problem of infertility. In 2022, they closed a $2.5m Seed round. Hear how👇

Super excited to back Bioptimus, spining off from our portfolio company Owkin with a $35m seed to build the world's first multi-scale foundation model for biology.

One-of-a-kind team, unparalleled access to data & knowledge.

Congrats Thomas Clozel, Jean-Philippe Vert,…

Looking forward to some great science with a great team !

Find out more about how Owkin is tackling #data and #healthcare challenges in Thomas Clozel’s article on World Economic Forum’s blog:

weforum.org/agenda/2024/01…

Owkin's data science team—Etienne Andrier, Valentina Di Proietto, Jean-Baptiste Schiratti, and former employee Simon Jegou—ranked 1st in a Kaggle UBC-OCEAN competition, showcasing the immense potential of #foundationmodels in medical research🏅

Outperforming 1,300 global…

L’hôpital Bicêtre AP-HP intègre une solution d’IA de Owkin pour améliorer la prédiction des rechutes du cancer du sein
aphp.fr/contenu/lhopit…

🔬 'How AI Can Tackle Cancer' - Thomas Clozel (@OwkinScience): Unlock collective intelligence for biotech innovation. Open the system for cross-fertilization! 🤝

Great blog post by Charlie Saillard explaining the amazing scientific journey that led to a clinically deployed diagnostic tool using digital pathology for pre-screening MSI status. The validation work has been published in Nature Comm.

And many other diagnostic tools to come!

We are excited to welcome 10x Genomics as part of the Mosaic research study – our landmark project to create the world's largest #spatial and #multiomics atlas in cancer.

Combined with our #AI capabilities, the addition of 10x Genomics’ Visium technology for…

We're excited to announce our landmark partnership with Servier to use #AI to advance novel therapies across multiple disease areas, including #oncology .

Our partnership combines Owkin's validated AI expertise with Servier's extensive #clinicaldata and scientific and…

I refuse to appear at Web Summit and am canceling my appearance.

I condemn Hamas and pray for peace for the Israeli and Palestinian people.

We are seeking talented 💻 Software Engineers and 🧬 Research Scientists to join our new Foundation Model R&D team. Listen to Jean-Philippe Vert, our Chief R&D Officer, as he introduces the team and shares our exciting missions.

Roles can be based in Paris, Nantes, London, or…

Read this insightful blog from Bristol Myers Squibb that explains our multi-year strategic collaboration to apply our #AI capabilities to design potentially more precise and efficient #clinicaltrials for BMS’ cardiovascular #drug pipeline.

Read the article at bms.com/our-stories/sc…